SMPX gene – Talk Bio

CSL Commits $117M for Option to Acquire VarmX and Advance Novel Blood Clotting Therapy to Market

2 days ago talkbio0Tagged Acquisition, Anticoagulants, antithrombin III, blood clotting drug, critical bleeding, Partnership, SMPX gene, United States Food and Drug Administration, VarmX, VMX-C001

CSL; VarmX; VMX-C001; blood clotting drug; Factor Xa inhibitors; anticoagulants; Phase 3 clinical trial; acquisition; biotech partnership; critical bleeding; FDA fast-track

CSL Announces Vaccine Unit Spin-Off and Major Workforce Cuts

4 weeks ago talkbio0Tagged cost-cutting, demerger, Seqirus, SMPX gene, strategic restructuring, Vaccines

CSL; Seqirus; vaccine spin-off; workforce reduction; demerger; strategic restructuring; biotech; cost-cutting

HHS ousts MAHA implementation lead amid rushed cancellations of $500M in mRNA vaccine contracts

1 month ago talkbio0Tagged BARDA, CHARGE Syndrome, Contract agreement, Gray Delany, MAHA, Moderna, mRNA contracts, Pfizer, Policy, Robert F. Kennedy, Seqirus, Shakeup, SMPX gene, Staff, terminations, Vaccines

HHS; MAHA; Gray Delany; mRNA contracts; BARDA; Robert F. Kennedy Jr.; vaccine policy; contract terminations; Moderna; Pfizer; CSL Seqirus; staff shakeup

FDA Approves CSL’s Andembry, Directly Competing With Takeda’s Takhzyro in HAE

3 months ago talkbio0Tagged Andembry, Angioedemas, Hereditary, Approved, dosing, factor XIIa, garadacimab-gxii, Inhibitor, SMPX gene, Subcutaneous Injections, Takeda, Takhzyro, United States Food and Drug Administration

Andembry; garadacimab-gxii; FDA approval; hereditary angioedema; HAE; CSL; Takhzyro; Takeda; factor XIIa inhibitor; once-monthly dosing; subcutaneous injection